http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Amgen (AMGN), Allergan (AGN) Submit BLA For ABP 798, Biosimilar Candidate To Rituxan, to FDA
-
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
-
Amgen (AMGN), UCB Announce EC Approves EVENITY for Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
-
European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
-
Amgen Announces 10% Increase In 2020 First Quarter Dividend
-
Amgen (AMGN) Reports Data from Phase 3 CANDOR Study Combining KYPROLIS (carfilzomib) And DARZALEX
-
Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting
-
Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub
-
Amgen (AMGN) Confirms FDA Approved its AVSOLA For Same Indications as Remicade
-
FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
-
Amgen Announces Data Being Presented At ASH 2019
-
Amgen (AMGN) Completes Acquisition Of Otezla, Updates Guidance
-
Amgen Completes Acquisition Of Otezla® (apremilast)
-
Bristol-Myers Squibb (BMY) Completes Acquisition of Celgene (CELG)
-
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
-
Amgen (AMGN), Cytokinetics (CYTK) Announces New Results From COSMIC-HF Presented at AHA
-
New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function
-
New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function
-
Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack
-
Bristol-Myers (BMY) Receives FTC Clearance for Celgene (CELG) Acquisition, Deal Expected to Close Next Week
-
Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition
-
Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors
-
Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio
-
Amgen To Present At The 28th Annual Credit Suisse Healthcare Conference
-
Amgen (AMGN) will acquire 20.5% stake in BeiGene (BGNE) for approximately $2.7 billion in cash
-
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
-
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
-
Amgen Reports Third Quarter 2019 Financial Results
-
Amgen Announces Webcast of 2019 Third Quarter Financial Results
-
Amgen (AMGN) to Make Repatha Available Exclusively at Lower List Price Option
-
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
-
Amgen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Corporation
-
Amgen (AMGN) CFO David Meline to Retire
-
David Meline, Amgen's Chief Financial Officer, To Retire
-
Amgen Announces 2019 Fourth Quarter Dividend
-
Amgen (AMGN) Announces Nplate Now Approved For Earlier Use in Adults With Immune Thrombocytopenia
-
Nplate® (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
-
Amgen (AMGN) Reports EVENITY (Romosozumab) Granted Positive CHMP Opinion for Treatment Of Severe Osteoporosis in Postmenopausal Women
-
EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
-
Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team
-
Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh
-
Amgen (AMGN) Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO
-
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019
-
Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?
-
Amgen To Webcast Investor Call At ESMO 2019
-
Amgen (AMGN) Reports Positive Results from Two Phase 3 BLINCYTO (blinatumomab) Studies Pediatric Patients with Relasped ALL
-
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
-
Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019
-
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
-
Amgen (AMGN) Announces Phase 3 CANDOR Study Combining KYPROLIS And DARZALEX Meets Primary Endpoint of PFS

